The Dark Side of Finasteride: What Men Deserve to Know About Mood, Neurosteroids, and Informed Consent

Finasteride: Commonly Prescribed, Rarely Questioned

Finasteride is a medication widely prescribed for male pattern hair loss and benign prostatic hyperplasia (BPH). While it is FDA-approved and often effective for both conditions, emerging evidence has raised concerns about persistent neuropsychiatric adverse effects, including depression, suicidality, and sexual dysfunction in a subset of patients. This is particularly concerning, given that finasteride is frequently prescribed for a non–life-threatening, cosmetic indication. More concerning still is that many men are not adequately educated about these potential risks, limiting their ability to make a fully informed decision before starting treatment.

How Finasteride Affects Brain Chemistry

Finasteride works by inhibiting the enzyme 5α-reductase, which converts testosterone into dihydrotestosterone (DHT), the most potent and androgenic form of testosterone in the body. For many men, blocking this enzyme leads to improvement in hair loss or BPH symptoms, but potentially at a significant physiological cost.

Importantly, 5α-reductase is not limited to hair follicles or prostate tissue. It also plays a critical role in the  brain, where it is involved in the synthesis of neurosteroids that regulate mood, stress resilience, and cognitive function. One such neurosteroid is allopregnenolone, a powerful neurochemical that acts on GABA receptors and has well-documented anxiolytic, antidepressant, and neuroprotective effects (Melcangi et al., 2017). By inhibiting 5α-reductase, finasteride reduces allopregnenolone synthesis, altering brain chemistry in a way that may contribute to mood and anxiety symptoms in some individuals.

Finasteride Studies: What the Evidence Shows

A growing body of high-quality research suggests that finasteride can be associated with severe and, in some cases, persistent adverse effects. Post-finasteride syndrome (PFS) is a term used to describe a constellation of ongoing physical, sexual, neurological, and psychiatric symptoms that persist after discontinuation of the medication (Traish, 2020). While PFS remains controversial in some medical circles, the consistency of reported symptoms and emerging mechanistic data warrant serious consideration.

One of the most compelling studies examining psychiatric outcomes found that among former finasteride users with persistent sexual side effects, 75% reported depressive symptoms, 64% had moderate-to-severe depression, and 44% reported suicidal ideation. In contrast, rates in matched control subjects were 10%, 0%, and 3%, respectively (Irwig et al., 2012). These findings suggest a striking association between finasteride exposure and clinically significant mood disturbances.

Notably, concerns regarding finasteride’s neuropsychiatric effects are not new. As early as 2002, reports began to surface linking finasteride to depressive symptoms, and in 2011 the FDA updated the drug’s label to include warnings about depression and suicidality. Despite this, widespread prescribing continues, often without a meaningful discussion of these risks.

A Functional Psychiatry Perspective

From a functional psychiatry perspective, the growing literature on finasteride resembles other areas of medicine, such as antidepressant withdrawal, where patient-reported harms preceded broad acknowledgment amongst health care providers. This pattern is reinforced by a passionate recent review published in The Journal of Clinical Psychiatry (2025), which explored decades of data and highlighted consistent associations between finasteride use, depression, and suicidality. Functional psychiatry providers understand the importance of biochemical individuality and how a given patient’s stress resilience, psychiatric history, metabolic health, inflammatory burden and other factors can influence how they may respond to disruptions in neurosteroid pathways.

Clinical Takeaways

Accumulating literature is elucidating that finasteride’s effects extend beyond hair follicles and prostate tissue and its brain-specific effects have long gone underappreciated. Emerging data suggests that for some, interference with neurosteroid pathways may lead to severe and persistent neuropsychiatric adverse effects. This does not mean finasteride should never be prescribed, but it does highlight the need for individualized risk assessment, transparent informed consent, and close monitoring over time.